{"nctId":"NCT00469417","briefTitle":"Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma","startDateStruct":{"date":"1999-10-18","type":"ACTUAL"},"conditions":["Superficial Basal Cell Carcinoma"],"count":120,"armGroups":[{"label":"Metvix速 PDT","type":"EXPERIMENTAL","interventionNames":["Drug: Metvix速 cream"]},{"label":"Cryotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Hand held liquid nitrogen spray cryotherapy"]}],"interventions":[{"name":"Metvix速 cream","otherNames":["Methyl 5-aminolevulinate hydrochloride"]},{"name":"Hand held liquid nitrogen spray cryotherapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nA participant with superficial BCC lesion(s) suitable for entry was defined as a participant with:\n\n* histologically confirmed diagnosis of primary superficial BCC lesion(s)\n* BCC lesions suitable for cryotherapy\n* males or females above 18 years of age\n* written informed consent. In accordance with Amendment 2 (local amendment), only participant above 19 years of age were to be included in Austria.\n\nExclusion Criteria:\n\nA participant or lesion fulfilling any of the following criteria was ineligible for inclusion:\n\n* prior treatment of the BCC lesion(s)\n* participant with more than 10 eligible BCC lesions\n* a superficial BCC lesion with the largest diameter exceeding 15 mm on face/scalp, larger than 20 mm on extremities and neck and larger than 30 mm on the trunk\n* a superficial BCC lesion with the largest diameter smaller than 6 mm\n* participant with porphyria\n* participant with Gorlin's syndrome\n* pigmented superficial BCC lesion(s)\n* morpheaform lesion(s)\n* infiltrating lesion(s)\n* participants with a history of arsenic exposure\n* known allergy to Metvix速, a similar PDT compound or excipients of the cream\n* participation in other clinical studies either concurrently or within the last 30 days\n* pregnant or breast-feeding; all women of child-bearing potential had to document a negative pregnancy test and use the pill or intrauterine device during the treatments and for at least one month thereafter\n* conditions associated with a risk of poor protocol compliance.\n\nIn Amendment 1 the following exclusion criteria were added:\n\n* xeroderma pigmentosum lesion\n* concurrent use of immunosuppressive medication.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT or Cryotherapy Cycle","description":"Patient Complete Response (CR) was defined as 100 percentage of the lesions within the participant having negative findings for nodular basal cell carcinoma (BCC) in the histological examination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Lesion With Complete Response 3 Months After Last Metvix PDT or Cryotherapy Cycle","description":"Complete response was defined as no clinically visible BCC lesions in the treatment area.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Cosmetic Outcome Assessed by Investigator 3 Months After the Last Metvix PDT or Cryotherapy Cycle","description":"Cosmetic outcome was assessed by both investigator and participants in participants with 100% of lesions in complete response. Overall cosmetic outcome was assessed with regard to occurrence of the following signs or symptoms; scarring, atrophy, induration, redness or change in pigmentation. The investigator graded the cosmetic outcome as:\n\n* excellent: no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared lo adjacent skin\n* good: no scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin\n* fair: slight to moderate occurrence of scarring, atrophy or induration\n* poor: extensive occurrence of scarring, atrophy or induration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Cosmetic Outcome Assessed by Participants 3 Months After the Last Metvix PDT or Cryotherapy Cycle","description":"Cosmetic outcome was assessed by both investigator and participants in participants with 100% of lesions in complete response. Overall cosmetic outcome was assessed with regard to occurrence of the following signs or symptoms; scarring, atrophy, induration, redness or change in pigmentation. The participants graded the cosmetic outcome as:\n\n* excellent: no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared lo adjacent skin\n* good: no scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin\n* fair: slight to moderate occurrence of scarring, atrophy or induration\n* poor: extensive occurrence of scarring, atrophy or induration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrence Rate in Complete Clearance Group","description":"Recurrence rate in complete clearance group was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Cosmetic Outcome Assessed by Investigator 24, 36, 48, and 60 Months After the Last Metvix PDT or Cryotherapy Cycle","description":"Cosmetic outcome was assessed by both investigator and participants in participants with 100% of lesions in complete response. Overall cosmetic outcome was assessed with regard to occurrence of the following signs or symptoms; scarring, atrophy, induration, redness or change in pigmentation. The investigator graded the cosmetic outcome as:\n\n* excellent: no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared lo adjacent skin\n* good: no scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin\n* fair: slight to moderate occurrence of scarring, atrophy or induration\n* poor: extensive occurrence of scarring, atrophy or induration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":60},"commonTop":[]}}}